Yield10 Bioscience Receives Favorable Ruling from the Argentine Biosafety Commission (CONABIA) for Company’s Camelina Lines
February 02 2022 - 8:30AM
Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the
“Company”), an agricultural bioscience company, today announced it
has received a favorable determination from the Argentine Biosafety
Commission (Comisión Nacional de Biotecnología Agropecuaria or
“CONABIA”) for three CRISPR genome edited Camelina lines.
CONABIA conducted an evaluation of three CRISPR genome edited
Camelina lines presented by Yield10 and determined that these
plants are similar to conventionally bred Camelina varieties, and
thus are not regulated under the biotechnology resolution No.
763/11 of the Ministry of Agriculture, Livestock and Fisheries in
Argentina. CONABIA confirmed that because Yield10’s edited Camelina
does not contain any foreign inserted DNA, this variety can be
marketed like conventionally bred Camelina which does not require
any pre-market authorizations. The Company’s CRISPR edited Camelina
lines covered by the CONABIA ruling are E3902 as well as two
distinct C3007 (BADC) Camelina lines developed by
Yield10. “This year we conducted
our first field tests of conventional elite Camelina germplasm in
Argentina, and now this favorable ruling from CONABIA streamlines
the process for growing our CRISPR genome edited Camelina lines in
Argentina as our seed scale up needs require,” said Kristi Snell,
Ph.D., Chief Science Officer of Yield10 Bioscience. “We are pleased
to see support for biotech innovation in agriculture as we bring
forward new traits to increase crop yield and introduce Camelina as
a new option for growers.”
Yield10 developed line E3902 and the two C3007 (BADC) Camelina
lines as part of its program to identify gene targets useful for
increasing oil content in oilseed crops. Yield10 researchers
produced line E3902 using CRISPR genome editing to modify three
genes involved in oil biosynthesis and oil turnover in Camelina. In
field trials to date, the E3902 Camelina line has shown a
consistent 5 percent increase in seed oil content as a percentage
of seed weight over control plants. The E3902 trait represents a
leading trait in Yield10’s pipeline and is currently being scaled
up to produce oil for sampling. The C3007 trait is at the field
testing stage in Camelina and canola to evaluate its activity as a
way to increase oil biosynthesis in oilseed crops. Yield10
previously cleared these Camelina lines from regulation in the U.S.
under the “Am I regulated?” process administered by the U.S.
Department of Agriculture Animal and Plant Health Inspection
Service (USDA-APHIS).
Argentina is a prominent player in agriculture as well as
aquaculture production. Soybean has become a critical crop for the
country as it is expected to produce an estimated 46 million
metric tons in 2022. Argentina possesses a suitable climate for
Camelina, making it ideal for growing as a cover crop in rotation
with soybean. CRISPR genome edited Camelina is a potentially high
impact crop for Argentinian growers with good market potential for
oil and meal production targeting the aquaculture market. CONABIA’s
favorable decision on Yield10’s CRISPR genome edited Camelina lines
is a significant step for Yield10’s elite Camelina lines to access
these markets.
About Camelina sativa
Camelina sativa, commonly known as Camelina or false flax, is an
annual oilseed plant in the mustard family that is native to
Europe. Camelina has the potential to replicate the development of
modern canola from rapeseed on an accelerated timeline based on
modern technologies, including genomics and genome editing.
Additionally, Camelina grows on marginal lands, displays early
maturation, has enhanced drought and cold tolerance, and requires
fewer inputs than other oilseed crops. With social conscience and
sustainability in mind, Yield10 is leveraging its innovations in
Camelina to use it as a platform crop for producing low-carbon
feedstock oil for renewable fuel; nutritional oil, including
omega-3; high-protein meal; and PHA bioplastic.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
that is using its differentiated trait gene discovery platform, the
“Trait Factory”, to develop improved Camelina varieties for the
production of proprietary seed products, and to discover high value
genetic traits for the agriculture and food industries. Our goals
are to efficiently establish a high value seed products business
based on developing superior varieties of Camelina to produce
feedstock oils, nutritional oils, and PHA bioplastics, and to
license our yield traits to major seed companies for
commercialization in major row crops, including corn, soybean and
canola. Yield10 is headquartered in Woburn, MA and has an Oilseeds
Center of Excellence in Saskatoon, Canada.
For more information about the company, please visit
www.yield10bio.com, or follow the Company on Twitter, Facebook and
LinkedIn.
(YTEN-G)
Safe Harbor for
Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, expectations related to Yield10’s Camelina lines
increasing oil content, crop yield and becoming a high impact crop
for Argentinian growers with good market potential for oil and meal
production, the CONABIA decision being a significant step for
Yield10’s elite Camelina lines to access markets, Yield10’s product
development and future licensing arrangements, and the overall
progress of Yield10, constitute forward-looking
statements. Such forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to
differ materially from those anticipated, including the risks and
uncertainties detailed in Yield10 Bioscience's filings with the
Securities and Exchange Commission. Yield10 assumes no obligation
to update any forward-looking information contained in this press
release or with respect to the matters described herein.
Contacts: Yield10 Bioscience:Lynne H. Brum,
(617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Jul 2023 to Jul 2024